Bryostatin-I: A dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine

Cytokine

Volumn 52, Issue 3, 2010, Pages 238-244

  Yan, Weili ^a,b   Chen, Weihsu C ^a,d,e   Liu, Ziming ^c   Huang, Leaf ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b AUBURN UNIVERSITY   (United States)

^c SICHUAN UNIVERSITY   (China)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Adjuvant; Bryostatin I; Cancer vaccine; Chemokine

Indexed keywords

ADJUVANT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BRYOSTATIN 1; CANCER VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN E7; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; BRYOSTATIN; CHEMOKINE; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPLEEN CELL; T LYMPHOCYTE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECT; ENZYME ACTIVATION; IMMUNOLOGY; METABOLISM;

HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRYOSTATINS; CANCER VACCINES; CHEMOKINES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79953302242     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.08.010     Document Type: Article

References (39)

1. Yan W., Huang L. Recent advances in liposome-based nanoparticles for antigen delivery. Polym Rev 2007, 47:16.
2. Guinn B.A., Kasahara N., Farzaneh F., Habib N.A., Norris J.S., Deisseroth A.B. Recent advances and current challenges in tumor immunology and immunotherapy. Mol Ther 2007, 15:1065-1071.
3. Pettit G.R., Herald C.L., Boyd M.R., Leet J.E., Dufresne C., Doubek D.L., et al. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem 1991, 34:3339-3340.
4. Berkow R.L., Kraft A.S. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun 1985, 131:1109-1116.
5. Kraft A.S., Smith J.B., Berkow R.L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci USA 1986, 83:1334-1338.
6. Clamp A., Jayson G.C. The clinical development of the bryostatins. Anticancer Drugs 2002, 13:673-683.
7. Jones R.J., Sharkis S.J., Miller C.B., Rowinsky E.K., Burke P.J., May W.S. Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro. Blood 1990, 75:1319-1323.
8. Lilly M., Tompkins C., Brown C., Pettit G., Kraft A. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res 1990, 50:5520-5525.
9. Do Y., Hegde V.L., Nagarkatti P.S., Nagarkatti M. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells. Cancer Res 2004, 64:6756-6765.
10. Li H., Wojciechowski W., Dell'Agnola C., Lopez N.E., Espinoza-Delgado I. IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways. J Immunol 2006, 177:3554-3563.
11. Ishida T., Oyama T., Carbone D.P., Gabrilovich D.I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol 1998, 161:4842-4851.
12. Mackay C.R. Chemokines: immunology's high impact factors. Nat Immunol 2001, 2:95-101.
13. Yoshimura T., Yuhki N., Moore S.K., Appella E., Lerman M.I., Leonard E.J. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett 1989, 244:487-493.
14. Carr M.W., Roth S.J., Luther E., Rose S.S., Springer T.A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994, 91:3652-3656.
15. Kim J.J., Nottingham L.K., Sin J.I., Tsai A., Morrison L., Oh J., et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 1998, 102:1112-1124.
16. Castellino F., Germain R.N. Chemokine-guided CD4+ T cell help enhances generation of IL-6Ralpha high IL-7Ralpha high prememory CD8+ T cells. J Immunol 2007, 178:778-787.
17. Castellino F., Huang A.Y., Altan-Bonnet G., Stoll S., Scheinecker C., Germain R.N. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006, 440:890-895.
18. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 2003, 77:8729-8735.
19. McKay P.F., Barouch D.H., Santra S., Sumida S.M., Jackson S.S., Gorgone D.A., et al. Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol 2004, 34:1011-1020.
20. Sumida S.M., McKay P.F., Truitt D.M., Kishko M.G., Arthur J.C., Seaman M.S., et al. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest 2004, 114:1334-1342.
21. Chen W., Yan W., Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother 2008, 57:517-530.
22. Yan W., Chen W., Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol 2007, 44:3672-3681.
23. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992, 176:1693-1702.
24. Byers A.M., Kemball C.C., Moser J.M., Lukacher A.E. Cutting edge. J Immunol 2003, 171:17-21.
25. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu Rev Immunol 1997, 15:749-795.
26. Kraft A.S., William F., Pettit G.R., Lilly M.B. Varied differentiation responses of human leukemia's to bryostatin 1. Cancer Res 1989, 49:1287-1293.
27. Mohammad R.M., Wall N.R., Dutcher J.A., Al-Katib A.M. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000, 6:4950-4956.
28. Zonder J.A., Shields A.F., Zalupski M., Chaplen R., Heilbrun L.K., Arlauskas P., et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res 2001, 7:38-42.
29. Song R., Liu S., Leong K.W. Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines. Mol Ther 2007, 15:1007-1015.
30. Thanarajasingam U., Sanz L., Diaz R., Qiao J., Sanchez-Perez L., Kottke T., et al. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res 2007, 67:300-308.
31. Wu H., Wang Y., Tay Y.C., Zheng G., Zhang C., Alexander S.I., et al. DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy. Kidney Int 2005, 67:2178-2186.
32. Flanagan K., Kaufman H.L. Chemokines in tumor immunotherapy. Front Biosci 2006, 11:1024-1030.
33. Lachman L.B., Ozpolat B., Rao X.M. Cytokine-containing liposomes as vaccine adjuvants. Eur Cytokine Netw 1996, 7:693-698.
34. Sasaki S., Takeshita F., Xin K.Q., Ishii N., Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods 2003, 31:243-254.
35. Keck G.E., Truong A.P. Synthetic studies on the bryostatins: synthetic routes to analogues containing the tricyclic macrolactone core. Org Lett 2005, 7:2153-2156.
36. Wender P.A., Koehler M.F., Sendzik M. A new synthetic approach to the C ring of known as well as novel bryostatin analogues. Org Lett 2003, 5:4549-4552.
37. Stone J.C., Stang S.L., Zheng Y., Dower N.A., Brenner S.E., Baryza J.L., et al. Synthetic bryostatin analogues activate the RasGRP1 signaling pathway. J Med Chem 2004, 47:6638-6644.
38. Cui Z., Qiu F. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 2006, 55:1270-1279.
39. Dileo J., Banerjee R., Whitmore M., Nayak J.V., Falo L.D., Huang L. Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther 2003, 7:640-648.